Clinical Cancer Research · 2016 · 61 citations · 33 references
Low-dose HDACi treatment can terminally differentiate MRT tumor cells and reduce their ability to self-renew. The use of low-dose HDACi as a novel therapeutic approach warrants further investigation. Clin Cancer Res; 22(14); 3560-70. ©2016 AACR.
33
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer
Isabella Versteege, Nicolas Sévenet, Julian Lange et al. · Nature · 1998 · 1.5K citations
HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo
Yu Zhang, Na Li, Cécile Caron et al. · The EMBO Journal · 2003 · 719 citations · Full text